CEL-SCI Corp. (CVM)
1.21
-0.26
(-17.69%)
USD |
NYAM |
Nov 20, 16:00
1.20
-0.01
(-0.83%)
Pre-Market: 20:00
CEL-SCI Enterprise Value : 22.65M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 22.65M |
| November 19, 2026 | 27.23M |
| November 18, 2026 | 25.64M |
| November 17, 2026 | 33.91M |
| November 16, 2026 | 30.57M |
| November 13, 2026 | 23.88M |
| November 12, 2026 | 22.30M |
| November 11, 2026 | 24.41M |
| November 10, 2026 | 26.17M |
| November 09, 2026 | 25.12M |
| November 06, 2026 | 26.88M |
| November 05, 2026 | 25.47M |
| November 04, 2026 | 25.64M |
| November 03, 2026 | 26.17M |
| November 02, 2026 | 24.41M |
| October 30, 2026 | 25.64M |
| October 29, 2026 | 27.75M |
| October 28, 2026 | 29.51M |
| October 27, 2026 | 28.99M |
| October 26, 2026 | 29.34M |
| October 23, 2026 | 30.22M |
| October 22, 2026 | 29.69M |
| October 21, 2026 | 29.87M |
| October 20, 2026 | 28.63M |
| October 19, 2026 | 30.39M |
| Date | Value |
|---|---|
| October 16, 2026 | 32.86M |
| October 15, 2026 | 31.98M |
| October 14, 2026 | 31.45M |
| October 13, 2026 | 32.15M |
| October 12, 2026 | 33.56M |
| October 09, 2026 | 35.49M |
| October 08, 2026 | 35.67M |
| October 07, 2026 | 38.84M |
| October 06, 2026 | 49.56M |
| October 05, 2026 | 43.94M |
| October 02, 2026 | 42.00M |
| October 01, 2026 | 38.13M |
| September 30, 2026 | 37.60M |
| September 29, 2026 | 32.86M |
| September 28, 2026 | 31.27M |
| September 25, 2026 | 30.74M |
| September 24, 2026 | 31.62M |
| September 23, 2026 | 30.92M |
| September 22, 2026 | 31.27M |
| September 21, 2026 | 30.74M |
| September 18, 2026 | 30.57M |
| September 17, 2026 | 27.58M |
| September 16, 2026 | 27.40M |
| September 15, 2026 | 27.40M |
| September 14, 2026 | 28.11M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 453.57M |
| Amgen, Inc. | 276.45B |
| Anika Therapeutics, Inc. | 158.39M |
| BioCryst Pharmaceuticals, Inc. | 2.302B |
| Imunon, Inc. | 6.224M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.668M |
| Total Expenses (Quarterly) | 5.668M |
| EPS Diluted (Quarterly) | -0.4678 |
| Earnings Yield | -213.5% |
| Normalized Earnings Yield | -213.55 |